ArticleJournal of thoracic disease2025
Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Chinese patients with advanced non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.World journal of surgical oncology · 2025Pooled it
- Efficacy and safety of sintilimab combined with histology-specific chemotherapy in advanced NSCLC: a real-world retrospective study.Frontiers in pharmacology · 2026Article
- From Innovation to Complication: A Case Report and Review on Immune-Related Colitis Induced by ICIs.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have significantly altered the first-line treatment paradigm for non-small cell lung cancer (NSCLC) without driver gene alterations. The efficacy and safety of different programmed cell death protein-1 (PD-1) inhibitors in the treatment of advanced NSCLC in Chinese real-world clinical practice remain unclear. This study aimed to analyze the efficacy and safety of camrelizumab, pembrolizumab, tislelizumab, and sintilimab retrospectively as first-line treatment options for advanced NSCLC in Chinese real-world applications. Methods: A total of 452 NSCLC patients treated with camrelizumab, pembrolizumab, tislelizumab, or sintilimab as first-line treatment between January 2019 and June 2023 in Jiangsu Cancer Hospital were retrospectively evaluated. Adverse events and patient responses were assessed using Common Terminology Criteria for Adverse Events v5.0 and Response Evaluation Criteria for Solid Tumors v1.1. The progression-free survival (PFS) was estimated using the Kaplan-Meier method or Cox survival regression model and compared using the log-rank test. Results: There were no significant differences in objective response rate (ORR) and median progression-free survival (mPFS) among the camrelizumab, pembrolizumab, tislelizumab, and sintilimab groups (ORR: 43.0% Conclusions: Camrelizumab, pembrolizumab, tislelizumab, and sintilimab possess similar efficacy as first-line treatment options for patients with advanced NSCLC in Chinese clinical practice. Any grade or grade ≥3 irAEs are comparable between the four PD-1 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.